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Received 26 September 2007; received in revised form 20 November 2007; accepted 26 November 2007AbstractBelgian Blue (BB) cattle are very sensitive to mange caused by Psoroptes ovis and, in contrast to the case in Holstein cattle,
single treatments with ivermectin do not result in complete elimination of the parasite. The objective of the present study was to
determine the concentration of ivermectin in plasma, skin and hair following subcutaneous administration to Holstein and BB
calves and to assess the influence of breed on drug pharmacokinetics and availability. Two groups of six healthy female Holstein and
BB calves were treated with ivermectin (SC formulation) at a dose of 0.2 mg/kg. Blood, skin and hair were collected before
treatment and up to 21 days after treatment. Ivermectin was analyzed in plasma and tissue by high-performance liquid
chromatography (HPLC). The peak concentrations (Cmax), time-peak concentrations (Tmax), the area under the plasma concentra-
tion–time curves (AUC) and the mean residence time (MRT) were determined. The patterns of plasma and tissue ivermectin
concentrations were similar in the two breeds of animals, however, the AUC and Cmax levels for plasma and skin were significantly
higher in the BB calves. In hair, ivermectin was detected later than in plasma and skin, with the Tmax ranging between 4 days
(Holstein group) and 6 days (BB group). The possible reasons for the significantly higher levels in plasma and skin in BB calves
compared to Holstein calves are discussed.
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doi:10.1016/j.vetpar.2007.11.021pharmacokinetic behaviour. The length of time during
which parasites are exposed to active drug concentra-
tions is important in determining optimal antiparasitic
activity (Hennesy and Alvinerie, 2002). Research on the
plasma kinetics and on the comparative plasma and
target tissue disposition kinetics (Lanusse et al., 1997;
Lifschitz et al., 1999, 2000) of ivermectin has
contributed greatly to the understanding of the
pharmacokinetics of the MLs. Several factors, such
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composition, have been shown to affect the systemic
availability of ivermectin substantially (Hennesy and
Alvinerie, 2002) in both sheep and cattle. Moreover,
important differences have been observed between the
pattern of absorption and systemic availability of
another ML – moxidectin – following topical admin-
istration in cattle of two different breeds, Aberdeen
Angus and Holstein (Sallovitz et al., 2002). It has also
been shown that the availability of ivermectin after
subcutaneous injection is low in zebu Gobra cattle (Bos
indicus) in comparison to other taurine (Bos taurus)
breeds of cattle (Ndong et al., 2005).
Belgian Blue (BB) cattle appear to be very sensitive
to Psoroptes ovis (Losson et al., 1999) and, unlike the
case in cattle of the Holstein (and other breeds), single
treatments with ivermectin do not always result in
complete elimination of the parasite (unpublished
results). The reason for this reduced efficacy is
unknown, but a possible explanation is that differences
in the systemic availability of ivermectin could lead to a
lower exposure of parasites to the drug in BB calves
compared to Holstein calves.
The objective of the present study was to determine
the plasma, skin and hair pharmacokinetics of
ivermectin after subcutaneous administration to Hol-
stein and BB calves and to assess the influence of the
animal’s breed on drug availability. Skin and hair were
included in the kinetic studies as the efficacy of the MLs
against ectoparasites in animals largely depends on the
distribution of the drug in the peripheral tissues (e.g.
skin) (Hennesy and Alvinerie, 2002). It has also been
demonstrated in humans that the efficacy of ivermectin
against scabies largely depends on its secretion in
sebum (Haas et al., 2002).
2. Materials and methods
2.1. Animals
Two groups of six healthy female Holstein and BB
calves were used. The Holstein calves were between 5
and 6 months old and weighed between 147 and 181 kg,
the BB calves were between 5 and 9 months old and
weighed between 153 and 283 kg.
2.2. Experimental design
On day 0 all calves were treated with ivermectin
(Ivomec1, Merial Belgium N.V., SC formulation) at a
dose of 0.2 mg/kg subcutaneously in the neck on the
right side. Blood was collected in heparin tubes(Venoject1, lithium heparin, Terumo) before treatment
(day 0) and 12 h, 1, 2, 4, 8, 10, 12, 14, 18 and 21 days
after treatment. Hair and skin (at least 1 g/animal) were
collected before treatment and at 1, 4, 8, 14 and 21 days
after treatment. Hair was collected alternating on the
left and right side of the back with a clipper (blade size
nr 40). Skin samples were taken from the clipped areas.
A ring block was applied around the biopsy site with 5
to 7 ml of procaine HCl 4% (VMD, Belgium) and a full
thickness skin sample (approximately 2 cm2) was
excised. Subcutaneous fat tissue, if present, was
removed from the sample, excess blood was drained
by placing the sample on a sterile compress and the
biopsy site was sutured with Dexon1 2-0. Fluids and
tissue samples were stored at 20 8C.
2.3. Analytical procedures
Residues of ivermectin in biological fluids are stable
for up to one year after freezing (Cerkvenik et al., 2004)
and the analysis of ivermectin in thefluids and tissueswas
performedwithin 3months of collection. Ivermectin was
analyzed in plasma and tissue by high-performance
liquid chromatography (HPLC) with automated solid
phase extraction and fluorescence detection according to
a previously described method (Lifschitz et al., 2000).
Briefly, fluid or tissue sample aliquotswere homogenized
in acetonitrile (Ultra Turrax T25 basic, Labortechnik).
The homogenate was mixed 20 min, sonicated 10 min
(UltrasoundBath) and centrifuged at 2000  g for 2 min.
The supernatant obtained was submitted to an automated
phase extraction and placed on a Benchmate apparatus
(BenchMate II, Zymark, Hopkinton, MA, USA) (Alvin-
erie et al., 1998). Fluorescent derivative was obtained by
dissolving the eluent in N-methylimidazole and trifluor-
oacetic anhydride (Aldrich, Milwaukee, WI, USA)
solutions in acetonitrile. Thechromatographic conditions
included a mobile phase of acetic acid 2%, methanol,
acetonitrile (4:32:64, v/v/v) pumped at a flow rate of
1.5 ml/min through a Supelcosil C18, 3 mm column
(150 mm  4.6 mm) (Supelco, Bellefonte, PA, USA).
Fluorescence detection (Detector RF 551, Shimadzu,
Kyoto, Japan) was performed at 365 nm excitation and
475 nm emission wavelength. The validation of the
technique was performed by using drug free calf plasma,
hair or skin tissue that were fortified with ivermectin in
the range of 0.1–50.0 ng/g for plasma (Lanusse et al.,
1997) and 0.5–50.0 ng/ml for both tissues (Lifschitz
et al., 2000). In the plasma, the recovery of the technique
was 77.7  8.8%, the linearity was r = 0.99 over a 0.1–
50.0 ng/ml concentration range (n = 6), the coefficient of
variation (CV) was 4.1 and the limit of quantitation
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Fig. 2. Concentration–time profile (skin) of subcutaneous adminis-
tered ivermectin in Holstein or BB calves at dose rate of 0.2 mg kg1.
Fig. 3. Concentration–time profile (hair) of subcutaneous adminis-
tered ivermectin in Holstein or BB calves at dose rate of 0.2 mg kg1.(LOQ) was 0.05 ng/ml. In the skin and in hair, the
recoverieswere 76.8  13.2%, and75.5  8.9%, respec-
tively, the linearity r = 0.99 (0.5–50.0 ng/g, n = 4) was
very close for the two tissues, the CVs were 6.3 and 11.0,
LOQ was 0.1 ng/g, similar for the three tissues.
2.4. Pharmacokinetic and statistical analysis of the
data
The peak concentrations (Cmax) and time-peak
concentrations (Tmax) were read from the plotted
concentration–time curve for each animal. The area
under the plasma concentration–time curves (AUC) from
time zero to the last time t with a measurable concen-
tration (Cp) were calculated using the linear trapezoidal
rule. The mean residence time (MRT) was calculated
using the linear trapezoidal rule with extrapolation to
infinity (Kinetica 4.4.11, Thermo Electron Corporation,
Waltham, USA), using the formula:
MRT ¼ AUMC
AUC
where AUMC is the area under themomentum curve and
AUC the area under the plasma concentration–time
curves from zero to infinity, as previously defined. The
pharmacokinetic parameters are reported as mean 
standard deviation. Data were subjected to statistical
analysis using Kruskal–Wallis test performed with the
Instat 2.01 software (Graph PAD, San Diego, USA).
Values were considered significantly different at
P < 0.05.
3. Results
The plots of the mean plasma, skin and hair
concentration versus time of ivermectin after subcuta-
neous administration of 0.2 mg/kg are shown in
Figs. 1–3, respectively. The pharmacokinetic para-Fig. 1. Concentration–time profile (plasma) of subcutaneous admi-
nistered ivermectin in Holstein or BB calves at dose rate of
0.2 mg kg1.meters that describe the disposition of ivermectin are
reported in Tables 1–3 for plasma, skin and hair,
respectively.
In plasma, ivermectin concentration was maximal
the 2nd day post-treatment and decreased slowly with
time. By day 21 post-treatment, the residual plasma
concentrations were low in both groups (0.5–1.0 ng/
ml). Fig. 1 shows a parallel plasma profile for the two
groups of animals, with higher plasma levels in BB
calves, resulting in significantly higher area plasma
concentration versus time curve (AUC) and maximal
plasma concentration (Cmax) as reported in Table 1. In
skin ivermectin was detected at the first sampling time
(day 1) and reached a maximal level on in the sampleTable 1
Plasma pharmacokinetic parameters of ivermectin in Holstein and BB
calves after a single subcutaneous administration at dose rate of
0.2 mg kg1
Parameter Holstein (n = 6) Belgian Blue (n = 6)
AUC0-last (ng day ml
1) 224.24  27.58 328.43  52.48
Cmax (ng ml
1) 31.87  7.23 49.51  10.76
Tmax (days) 1.83  0.37 2.33  0.75
Thalf (days) 3.00  0.57 3.17  0.84
MRT total (days) 5.80  1.14 6.16  1.87
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Table 3
Hair pharmacokinetic parameters of ivermectin in Holstein and BB
calves after a single subcutaneous administration at dose rate of
0.2 mg kg1
Parameter Holstein (n = 6) Belgian Blue (n = 6)
AUC0-last (ng day g
1) 51.57  37.42 58.65  18.80
Cmax (ng g
1) 4.10  3.42 5.96  2.27
Tmax (days) 4.57  2.09 6.67  2.07
Thalf (days) 7.25  1.67 4.03  1.99
MRT total (days) 9.55  2.91 19.51  13.12
Table 2
Skin pharmacokinetic parameters of ivermectin in Holstein and BB
calves after a single subcutaneous administration at dose rate of
0.2 mg kg1
Parameter Holstein (n = 6) Belgian Blue (n = 6)
AUC0-last (ng day g
1) 81.28  7.71 126.62  17.46
Cmax (ng g
1) 9.93  1.67 15.01  4.36
Tmax (days) 3.5  1.22 5.33  2.07
Thalf (days) 3.0  0.60 3.15  1.04
MRT total (days) 6.48  1.17 5.69  1.35taken on the 4th day post-treatment. As observed for
plasma the maximal skin levels were significantly
higher in BB calves (Cmax: 126.62  17.46) compared
to Holstein calves (Cmax: 81.28  7.71). Fig. 2 shows
the skin concentration profiles, which are similar to the
plasma concentration profiles, but with a lower
concentration range. In hair ivermectin was detected
later than in plasma and skin, with a Tmax of 4 days in the
Holstein group and 6 days in the BB group (Table 3).
4. Discussion
For both breeds, we observed a parallel distribution
of ivermectin in skin and plasma, due to the continual
exchange of drug between the two tissues, as previously
described by others (Lifschitz et al., 2000). The
ivermectin concentrations in the target tissues were
lower in the Holstein group compared with BB group, in
agreement with the observed differences in plasma
concentrations. The ivermectin distribution in hair
probably originates via sebum secretion, as previously
reported in humans with scabies after oral treatment
with ivermectin (Haas et al., 2002). This feature
probably accounts for the high efficacy of ivermectin
against ectoparasites.
In the current trial the systemic availability of
ivermectin was statistically different between the two
cattle breeds studied. In cattle, breed and race
differences in drug kinetics have been reported in thepast (Ndong et al., 2005; Sallovitz et al., 2002).
Important differences in the pattern of systemic
availability of moxidectin after topical administration
have been observed between Aberdeen Angus and
Holstein breeds (Sallovitz et al., 2002). Differences in
skin physiology, inherent to these breeds, were
suggested as a possible explanation for the different
systemic availability. In the present study ivermectin
was administered subcutaneously and therefore our
results suggest that factors other than skin physiology
may affect pharmacokinetic differences between
breeds. The pharmacokinetic behaviour of subcuta-
neously administered ivermectin has been investigated
in West African breeds cattle (Ndong et al., 2005) and
the AUC for ivermectin in zebu Gobra cattle was lower
in comparison to other cattle breeds, presumably due to
specific anatomical or physiological characteristics of
this breed.
However, the reasons for the significantly higher
levels in plasma and skin in BB calves group compared
to Holstein calves are difficult to explain. For a given
drug formulation administered by a certain route, many
animal-related factors will determine differences in
pharmacokinetic behaviour. Among these factors
differences in body composition have been suggested
as a cause of differences in ivermectin pharmacoki-
netics between individuals and species due to the highly
lipophilic nature of the drug. The higher fat content of
Holstein carcasses compared to BB carcasses (28.3%
versus 15.4%, Istasse et al., 1990) might explain the
difference in peak plasma concentrations (Cmax). In
fact, injected ivermectin could have accumulated in the
fat of the subcutaneous injection site in the Holstein
calves, while injected ivermectin in the BB cattle could
have reached directly the systemic circulation. A faster
absorption could explain the higher value of the AUC in
BB calves compared to Holstein calves. The elimination
process, however, was quite similar in the two breeds, as
indicated by the elimination half-life values. This
corresponds with previous results demonstrating that in
cattle metabolism of ivermectin is limited and that the
major excretion product in faeces is the parent
compound (Chiu et al. (1987). Therefore, a possible
difference in metabolism between Holstein and BB
seems unlikely.
The binding of drugs to plasma components is also a
determinant of interest in the pharmacokinetic profile.
The plasma binding of ivermectin and other related
macrocyclic lactones is mainly due to association with
high-density lipoproteins (HDL) (Bassissi et al., 2004)
whereas binding to albumin is of minor importance
(Audus et al., 1992). In various animal species (cattle,
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pattern of MLs to lipoproteins was reported (Bassissi
et al., 2004), consequently this is unlikely to be the
cause of the breed differences in pharmacokinetics.
The minimal concentration of ivermectin required
at the target tissues (e.g. skin) to inhibit the
development of parasites (e.g. scabies) has not been
determined. However, the higher concentration of
ivermectin in BB, compared to Holstein calves,
suggests that the lower efficacy of ivermectin against
psoroptic mange is not related to drug availability at
the target site. A different skin reaction pattern against
P. ovis in BB cattle compared to Holstein cattle could
also explain the apparent reduced efficacy of iver-
mectin in this breed. Losson et al. (1999) showed that
an intradermal injection of Psoroptes cuniculi antigen
in P. ovis-infected BB and Holstein cattle resulted in a
delayed hypersensitivity reaction only in BB cattle.
This may explain the more severe and prolonged skin
reactions observed in this breed during a Psoroptes
infestation.
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